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I.1   67LR: isolation and structure  
In 1983, three independent laboratories isolated a non-integrin 67kDa 
protein, designated the 67kDa laminin receptor (67LR), by affinity 
chromatography on laminin-Sepharose (1-3). To date, the structure of this 
molecule has not yet been fully elucidated, and only the cDNA encoding a 
cytoplasmic 37kDa precursor (37LRP) has been identified (4).  Pulse-chase 
experiments performed on melanoma cells demonstrated that this 37kDa 
polypeptide is the precursor of the 67kDa form (5), and the post-traslational 
mechanism by which the 67LR is synthesized from the precursor has been 
shown to consist in the acylation of the precursor and formation of homo-or 
heterodimers (6, 7). Based on the amino acid sequence of the 37LRP, a 
transmembrane domain (residues 86-101) and several laminin binding sites 
have been identified, consisting of a palindromic sequence, LMWWML, 
known as peptide G (8), a predicted helical domain corresponding to 
residues 205-229, and TEDWS-containing C-terminal repeats (9).  
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The specific site of 67LR interaction with laminin has been also identified; it 
resides in the sequence YIGSR, located on the short arm of laminin (10). 
 
I.2   67LR: gene cloning 
The human 37LRP gene has been mapped by fluorescence in situ 
hybridization to 3p21.3, a chromosomal locus frequently involved in 
karyotipic rearrangements associated with cancers (11). 37LRP gene 
contains seven exons and six introns with multiple transcription start sites. 
The promoter area does not bear a TATA box but contains four Sp1 sites. 
The first intron is also GC rich, containing five Sp1 sites. Intron 4 contains 
the full sequence of the small nuclear RNA E2, and two Alu sequences are 
found in intron 3. 37LRP gene shows a close correspondence with genes 
encoding the ribosomal protein p40 (12), which is a component of the 
translational machinery associated with the 40S ribosomal subunit. The 
amino acid sequence corresponding to the 37LRP cDNA is extremely 
conserved during evolution (13). 37LRP homologs among mammalian 
species (e.g., bovine, rat, mouse, human and hamster) all have an intact 
laminin binding domain, located in the carboxy-terminal part of the 
molecule, and share 99% homology (14). It is an intriguing feature that the 
homology of all the non mammalian 37LRP/p40 homologs with the 
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mammalian polypeptides is limited to the aminoterminal part of the 
molecule, due to a lack of the carboxy-terminal laminin-binding domain. 
Therefore, it has been proposed that, during evolution, the 37LRP/p40 gene 
gained in vertebrates a sequence encoding a laminin binding domain that is 
responsible for the appearance of a new function such as cell-matrix 
interaction (15).   
 
I.3   Relationship between the 67LR, integrins, and laminin 
A few years after the initial description of the 67LR as a laminin receptor, 
integrins were identified as primary mediators of cell adhesion and signal 
transduction to the nucleus.  Actually, many studies have addressed the issue 
of the respective roles of these two types of receptors in mediating cell-cell 
or cell-matrix interactions.  It has been shown that 67LR and VLA6 are co-
expressed, co-regulated, and physically associated on the cell surface, 
suggesting their mutual involvement in laminin binding (16, 17). In fact, in 
A431 epidermoid carcinoma cells a6 antisense oligonucleotides, which 
downmodulate integrin expression on the membrane, also proportionally 
reduced 67LR membrane expression.  This regulation occurred at the level 
of protein translocation from the cytoplasm to the membrane. Moreover, 
treatment with laminin, which increases 67LR expression, also increased the 
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membrane expression of laminin-specific integrins. On the cell membrane, 
the 67LR and the a6b4 receptor are physically associated, as demonstrated 
by coprecipitation experiments (17), thus suggesting a possible synergistic 
role of the two receptors in laminin recognition. In fact, peptide G, which 
contains the laminin-binding sequence of 67LR (8), increases and stabilizes 
laminin binding to tumor cells, possibly by changing laminin conformation 
to favor integrin binding (18).   
 
I.4   Regulation of 67LR expression 
Laminin receptor expression was found to be down-regulated during 
differentiation (19, 20) and up-regulated by cytokines and inflammatory 
agents (21).  Up-regulation of the 67LR was also detected after interaction of 
cells with extracellular matrix proteins; human cell lines derived from breast  
cancer have increased levels of 37LRP mRNA after exposure to 
extracellular matrix proteins such as laminin and fibronectin (22).  
Moreover, a positive feed-back loop links the presence of laminin with 
increased 67LR expression (23). Steroid hormones have also been found to 
up-modulate 67LR expression in hormone-receptor positive cell lines, 
whereas hormone-receptor negative lines constitutively express high levels 
of 67LR (24). 
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It has been recently reported that the 67LR gene is overexpressed during 
transformation induced by anti-benzo[a]pyrene-7,8-diol-9,10-epoxide (25).  
 
I.5   67LR in tumor progression 
The strong correlation observed between increased 67LR expression and the 
metastatic potential of tumor cells suggests that this receptor plays a key role 
in development of the metastatic phenotype (26, 27). 67LR is expressed in a 
variety of human carcinomas (for example, breast, colon, lung, thyroid) and 
its over-expression is widely recognized as a molecular marker of metastatic 
aggressiveness (28). As its expression level correlates with the risk of 
invasion and metastasis and with malignant dissemination to the BM, 67LR 
is now considered to be an indipendent prognostic marker in breast 
carcinomas (29).  
Given its prominent role in tumor metastasis, new therapies that utilize 
antagonists of 67LR have been tested in mouse (30) and anti-67LR immuno- 
therapies have been experienced in metastatic human renal carcinoma (31) 
and proposed for hematological malignancies (32).  
Concerning hematopoietic malignancies, laminin acts as a chemoattractant 
for multiple myeloma (MM) cells by interaction with the 67LR and this 
interaction is important for the extravasation and homing to BM of 
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circulating MM cells (33). The 67LR is also expressed in monocytic acute 
myeloid leukemias (34) and in T cell lymphomas (35).   
The role of 67LR in tumor progression is based on the adhesion properties 
mediated by this receptor.  The recent view of tumors as a functional tissue 
interconnected with the microenvironment suggests that the remodelling of 
the extracellular matrix (ECM) around the tumors is important in tumor 
invasion and dissemination to distant sites (36).  In fact, a key step in the 
metastatic process is the attachment of tumor cells to laminin, the major 
component basement membranes. Interactions between tumor cells and 
basement membranes are mediated by specific membrane receptors, 
including the 67LR. During intra-vasation and extra-vasation, cancer cells 
need to come into contact with and to degrade host basement membranes, 
before passing through. Proteolytic degradation of basement membrane 
components such as proteoglycans, collagen type IV, laminin-1, and 
laminin-5 occurs through the action of specific proteases secreted by tumor 
and stromal cells.  This proteolytic cleavage removes physical barriers to 
cell migration and converts ECM components in substrates suitable for 
migration (37).  The invasive behaviour of metastatic tumor cells correlates 
with the expression of many enzymes with hydrolytic activity, such as 
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cysteine proteinases, cathepsin B, aspartic proteinases, cathepsin D, serine 
proteinases, and elastase (38, 39).  
67LR binding to laminin enhances tumor-cell motility (40, 41) by 
determining a conformational modification of laminin, which increases its 
degradation rate and the release of chemotactic fragments (42). In addition, 
67LR increases cancer cells invasion by up-regulating the expression and the 
activity of proteolytic enzymes able to degrade the extracellular matrix, such 
as membrane type 1 matrix metalloproteinase (MT1-MMP), stromelysin 3, 
cathepsin L, and the matrix metalloproteinase MMP-2 (43).  
  
I.6    The hematopoietic stem cell  
Stem cells are generally defined as cells capable of both self-renewal and 
mega- and multilineage differentiation. Self-renewal is the unique ability to 
produce daughter cells that retain stem-cell properties (44). The science of 
embryology has distinguished two type of stem cell: embryonic stem cell 
and adult stem cell (45). The term embryonic stem cell (ES) indicates a 
population obtained from embryos and pluripotent in that they can produce 
an embryo.  Adult stem cell, instead, has been thought to give ris e to cells 
committed to specific tissues (46).  They have a limited ability to self-
renewal with the exception of hematopoietic stem cells. Recently, studies 
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have suggested the existence of stem cells in many adult tissues such as the 
central nervous system (47, 48), lung (49, 50), liver (51), pancreas (52), and 
vascular system (53), in which the self-renewing is necessary after trauma, 
disease or aging (54). Adult stem cells also present the plasticity, as the 
ability of a cell to cross over its identity from one organ to another (55).  
Mature blood cells are produced continuously by less-differentiated 
precursors that, in turn, descend from more primitive progenitors and, 
originally, from hematopoietic stem cells.  Hematopoietic stem cells can be  
divided into a long-term subset, capable of indefinite self-renewal, as well as 
a short-term subset that self-renews for a defined interval. During late 
embryonic development, hematopoietic stem cells migrate towards blood 
circulation from the fetal liver to the bone marrow, where they are 
maintained throughout life.  
The current stem cell model identifies two main stem cell populations with 
distinct progenies housed within the bone marrow, named hematopoietic 
stem cells (HSCs) and mesenchymal stem cells (MSCs).  The HSCs include 
all lymphoid and myeloid lineages that produce blood circulating cells and 
organ-resident cells of the immune response, and are regulated by the BM 
microenvironment. This microenvironment is composed of osteoblasts, 
adipocytes, endothelial and vascular cells (56, 57).  
________________________________________________________________ 
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HSCs are largely absent from peripheral blood (PB), except for a small pool 
of circulating HSCs whose physiological role in steady-state homeostasis is 
still unknown. One HSC can restore the entire lympho-hematopoietic 
system.  Therefore, transplantation of marrow HSCs has been largely 
employed in a wide variety of acquired neoplastic and non-malignant 
disorders to reconstitute the hematopoietic system after chemotherapy and/or 
radiation.  
 
I.7   Stem cell mobilization 
The first source of HSCs for transplantation purposes was the bone marrow, 
obtained by repeated aspiration of the posterior iliac crests while the donor is 
under general or local anesthesia.  This procedure has not serious side effects 
and the discomforts are rare.  
HSCs can also be collected from the peripheral blood. Under steady-state 
conditions the number of HSCs is much lower in peripheral blood than in 
bone marrow. Chemotherapy and/or cytokine administration may lead to a 
concentration of HSCs in the peripheral blood that equals or exceeds the 
concentration in bone marrow. This process mimics the enhancement of the 
physiological release of stem and progenitor cells from the bone marrow 
reservoir in response to stress signals during inflammation (58) and is 
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termed “mobilization”.  Currently, mobilized HSCs are the preferable and 
major source of stem cells harvested for autologous and allogenic 
transplantations, because of faster engraftment and decreased procedural 
risks.  
Generally, peripheral blood stem cells are obtained by apheresis via a 
peripheral venous access. These HSCs, or better progenitor cells, are mostly 
expressed as the percentage of cells than react with CD34 antibodies or that 
form colonies in a semi-solid medium. A single apheresis procedure can 
bear to 3.7 times more CD34+ cells than the standard bone marrow harvest.  
Clinical studies have shown that infusion of at least 2x106 CD34+ cells/kg 
recipient body weight results in reliable engraftment after 14 days from 
transplant (59). Normally, mobilized HSCs represent a subpopulation of all 
CD34+ cells found in the circulation; these very primitive cells do not 
express CD38 and lineage-specific markers, but a small subset can express 
the Thy-1 antigen. This CD34+/CD38-/Lin-/Thy+1 population is 
characterized by high repopulating activity in NOD/SCID mice and is 
enriched in cells initiating long-term cultures (LTC-IC) in vitro (60), 
representing the best surrogate of BM hematopoiesis in vivo. 
The road to stem cell mobilization began in the1960s, with publication of a 
few reports documenting the presence of HSCs in the peripheral blood of 
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mice, dogs, and monkeys, followed by reports revealing low levels of 
progenitors in the human circulation during steady-state homeostasis. A 
transient increase in circulating progenitors was documented in dogs treated 
with dextran sulfate and humans treated with endotoxin or other stress-
inducing agents.  These results were followed by preliminary reports in the 
late 1970s documenting increased levels of progenitors in the circulation of 
patients after chemotherapy treatment with cyclophosphamide and other 
drugs. Technical improvements, including in vitro colony assays and the 
availability of large-scale harvesting of human progenitors by continuous-
flow leukapheresis, enabled closer examination of chemotherapy/drug 
induced mobilization in treated patients. Clinical studies of To and his group 
were the first to document the beneficial faster repopulation in patients 
transplanted with autologous mobilized peripheral blood HSCs (61). 
Initially, the mobilization protocols were based on chemotherapy alone. 
After the discovery of human granulocyte colony stimulating factor (G-CSF) 
by Welte et al, mobilization protocols began to include G-CSF, which today 
is the standard mobilizing agent (62). This is because it has been shown to 
both mobilize more CD34+ cells and have less toxicity in comparison with 
other single agents.  G-CSF is commonly administered daily at a dose of 5-
10 mg/kg for 5-10 days, alone or after chemotherapy. Sometimes the kinetics 
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of mobilization identify the peak of CD34+ cell in circulation in 3-6 hours 
after each dose (46). Alternative agent used instead of G-CSF is sometimes 
granulocyte-monocyte colony stimulating factor (GM-CSF), but it is used 
less than G-CSF, because it mobilizes less well and because of a higher 
incidence of mild and severe effects (63).  Stem cell factor (SCF) is another 
excellent mobilizing agent, expecially used in combination with G-CSF (64).  
A new mobilizing agent is AMD3100, a small reversible inhibitor of the 
binding of stromal derived factor (SDF-1a) to its receptor, CXCR4 (65, 66).  
 
I.8 Factors influencing stem cells mobilization 
The localization, as well as survival and proliferation/differentiation, of adult 
hematopoietic cells within bone marrow are vested on their relationships 
with microenvironmental cells and extracellular matrix. At steady state, 
proliferating hematopoietic cells in various stages of differentiation are 
confined within specialized BM "niches," whereas terminally differentiated, 
mature cells leave the BM and migrate into blood. In addition, a small 
proportion of morphologically unrecognizable primitive stem cells regularly 
escapes the BM and circulates throughout life. More importantly, the 
circulating pool of stem cells can increase in significant numbers by their 
enforced migration from BM using several interventions. Enforced 
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emigration of hematopoietic cells or "mobilization" has been observed in all 
species examined up to now, suggesting preservation of similar mechanisms 
of stem cell trafficking across species. Despite its significance and great 
clinical impact, the mechanisms of mobilization have not been fully 
elucidated yet. 
It appears that during mobilization the bone marrow becomes the 
playground of a complex interplay between cytokines/chemokines and their 
receptors, potent proteases, and adhesion molecules (67).  
-The role of proteases. Direct in vivo studies have shown that, after G-CSF 
treatment, neutrophils release the contents of either specific (ie, matrix 
metalloproteinase 9 [MMP-9] or lactoferrin) or azurophilic (elastase, 
cathepsin G, or proteinase 3) granules (68).  Lévesque et al showed that 
following G-CSF mobilization, serine proteases, especially neutrophil 
elastase, accumulate within the bone marrow environment, and their 
substrates included molecules implicated in mobilization, such as vascular 
cell adhesion molecule 1 (VCAM-1), c-kit, CXCR4 and its ligand SDF-1, as 
well as many components of ECM (69, 70, 71). In addition to serine 
proteases, metalloproteases or dipeptyl peptidase IV (DPPIV/CD26) are also 
known to cleave some of the same target molecules, including SDF-1 (72).   
Several subsequent studies were performed with mouse models deficient in 
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serine proteases, such as MMP-9, or DPP1, with mice bearing combined 
elastase and cathepsin-G deficiency, or with mice deficient in DPP1 and 
lacking functional activation of many neutrophil proteases. Each of these 
mice responded to G-CSF–induced mobilization to the same extent as 
control mice (73). To test whether other overlapping protease activities 
contributed to the response, MMP-9–deficient mice, or DPP1–deficient mice 
were treated with a broad spectrum of MMP inhibitors and G-CSF. Despite 
the expectation that combinations of deficiencies would greatly attenuate the 
response, G-CSF–induced mobilization was not impaired (73). 
Compensation by other proteases in these deficient animals was offered as 
an explanation.  
A common characteristic of all the protease-deficient mice responding to G-
CSF was a reduction of SDF-1 protein levels within the bone marrow, 
suggesting that reduction in SDF-1 may be the common denominator in G-
CSF–mediated response. The emerging picture from the studies with 
protease-deficient mice is that the contribution of a single protease may not 
be critical; a coalition of proteases within bone marrow seems to be required 
(68).  
- The role of chemokines. Mobilization has been achieved thus far with the 
use of several chemokines, such as IL-8, monocyte chemoattractant protein-
________________________________________________________________ 
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1 macrophage inflammatory protein 1a or 1b, Grob, SDF-1, or others (74). 
Mechanisms of chemokine mobilization have been explored only with the 
use of IL-8, Grob or SDF-1. The IL-8 and Gro responses appear to be 
dependent on adequate numbers and normal function of circulating 
neutrophils, and they are associated with increase of MMP-9, presumably 
released by mature neutrophils (75). In fact, the use of antineutrophil 
antibodies or of MMP-9 inhibitors greatly attenuated the response (76).   
Biologic responses to SDF-1 have been also extensively studied (77). 
Studies with SDF-1 or CXCR4 knock-out animals revealed important roles 
of the CXCR4/SDF-1 pathway in the active retention of hematopoietic cells 
within bone marrow. Furthermore, a number of subsequent studies suggested 
important roles in homing and stem cell mobilization, and SDF-1 has 
emerged as the most potent chemoattractant of hematopoietic 
stem/progenitor cells (78). Mobilization was seen using Met SDF-1 (an 
SDF-1 analog), which is refractory to cleavage/degradation and results in 
prolonged desensitization of CXCR4 (79).  On the other hand, adenovirus-
driven SDF-1 with release of high circulating levels of SDF-1 or 
administration of a peptide-agonist of SDF-1 (80) resulted in mobilization, 
presumably because of a change in SDF-1 gradient between bone marrow 
and peripheral blood (81). Further observations showed that AMD3100, a 
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small molecule inhibitor of CXCR4 which inhibits its binding to SDF-1 and 
disrupts the SDF-1–dependent signaling, induced significant mobilization 
both in mice and humans (82).  
Mobilization through the use of Met SDF-1 (83), or CXCR4 antagonists,  or 
following Pertussis toxin (Ptx) treatment (84), is likely mediated through 
down-regulation of the CXCR4 receptor and/or disruption of its signaling on 
hematopoietic cells. Further, truncation of SDF-1 by serine proteases or 
MMP-9, as demonstrated during G-CSF-induced mobilization, also inhibits 
SDF-1–dependent signaling in hematopoietic cells, rather than change the 
bone marrow to peripheral blood SDF-1 gradient.  
The preponderance of evidence thus suggests that inhibition of the 
CXCR4/SDF-1 signaling is a dominant pathway in G-CSF–induced 
mobilization.  
-The role of adhesion molecules. The most consistent difference between 
mobilized progenitor cells and steady-state BM cells is the absence of 
cycling cells and a decreased expression of very late activation antigen 4 
(VLA-4) and kit in mobilized cells (61). More important than the expression 
level, however, is the reduced functional state of VLA-4 receptors on 
mobilized HSCs (85). As the same functional change was also observed in 
bone marrow HSCs after G-CSF treatment, it invited the speculation that 
________________________________________________________________ 
___________________________________________________________________ 20 
this phenotype promotes transmigration. Whatever the predominant 
mechanism is, it is well accepted that migratory responses are mediated 
through integrin participation. Thus, one could envision that integrin 
(functional) down-regulation is a common step at the final stages of 
transmigration through the endothelial sinuses. Such a proposition is in line 
with VLA-4 involvement in firm retention of normal (86)  or leukemic cells 
within the bone marrow. The fact that inducible ablation of alpha4 integrins 
in adults leads to hematopoietic progenitor egress in mice (87)  further 
reinforces this concept. Like the down-regulation of alpha4 integrin, 
additional hallmarks of transmigrated cells are the down-regulation of 
CXCR4 receptor (88)  and hyporesponsiveness to SDF-1. This could suggest 
that transmigration can be efficiently achieved only in cells that have down-
regulated either their alpha4 integrin or CXCR4/SDF-1 function. It is 
important to emphasize that down-regulation of VLA-4 or CXCR4 receptor 
responses by themselves may not be sufficient to induce mobilization in all 
cells and additional complex interactions and cooperative signaling with 
other pathways involved in transendothelial migration (ie, small GTPases) 
may be necessary for the cells to exit the BM.  
In conclusion, mobilization sets in motion an intramarrow proteolytic 
machinery with participation of diverse cell-bound or free proteases, largely 
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liberated by mature cells, and acting on multiple target molecules located on 
hematopoietic or stromal cells and on their matrix (adhesion receptors, 
chemokines and their receptors, or signaling molecules, etc). Depending on 
the stimulus applied, several distinct pathways can initiate mobilization.  
However, there is a broad interdependency between the pathways initiating 
and/or amplifying mobilization. For example, proteases may affect each 
other's function (elastase affecting MMP-9 or MMP-9 affecting SDF-1, and 
vice versa), may target cytokine/chemokines receptors (CXCR4, kit) as well 
as their ligands (SDF-1, kit-ligand), or may additionally modulate integrins 
and endothelial structural components. It is evident, therefore, that there are 
large avenues open for future exploration. Unveiling the regulatory 
pathways in mobilization will not only reap clinical benefits, but greatly 
enhance our basic understanding of the concept of stem cell "niche", pivotal 















Mobilized hematopoietic stem cells (HSCs) are rapidly replacing traditional 
bone marrow (BM) harvesting as a source of stem cells for transplantation 
purposes.  Mobilization of HSCs from BM into the circulation is obtained by 
stimulation with growth factors and chemokines, administered either alone 
or in combination with chemotherapy. Over the past 5-10 years, granulocyte 
colony-stimulating factor (G-CSF) has emerged as the most widely used 
mobilizing agent because of its potency and safety.  
HSC mobilization is a multistep process that depend on a complex interplay 
between chemokines, growth factors, proteolytic enzymes and adhesion 
molecules. HSC express several adhesion molecules that are responsible for 
cell-cell and cell-matrix interactions. The 67 kDa laminin receptor (67LR) is 
a non-integrin cell-surface receptor with high affinity for laminin, which 
plays a key role in tumor invasion and metastasis.  
The aim of this project is to investigate the involvement of 67LR in G-CSF-
induced HSC mobilization. To this end, we analyzed 67LR expression and 
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function in G-CSF-mobilized HSCs from healthy donors, as compared to 
untreated BM HSCs. We also investigated the ability of neutralizing anti-



















§ III CHAPTER 
 
MATERIALS AND METHODS 
 
III.1 Reagents 
Horseradish peroxidase-conjugated anti-rabbit IgG were from BIORAD 
(Richmond, CO, USA); FITC-labelled goat anti-rabbit IgG were from 
Jackson Lab (West Grove, PA, USA).  Protease inhibitors, Ficoll-Hypaque 
(specific gravity 1077), bovine serum albumin (BSA) and hydrocortisone 
sodium hemisuccinate were from Sigma Chemical Co (St. Louis, MO, 
USA).  Human placental laminin (LM) was from Chemicon (Temecula, CA, 
USA).  The enhanced chemioluminescence (ECL) detection kit was from 
Amersham International (Amersham, England), polyvinylidene fluoride 
(PVDF) filters from Millipore (Windsor, MA, USA). RPMI 1640 medium, 
Medium 199, FN-coated culture flasks, heat-inactivated Fetal Calf Serum 
(FCS), LipofectAMINE, and Geneticin were from Life Technologies 
(Gaithersburg, MD, USA).  96-well microtiter plates and Transwell plates 
were from Costar (Cambridge, MA, USA).  Chemotaxis PVPF filters were 
purchased from Corning (NY, USA).  The stromal derived factor 
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1a  (SDF1) was purchased from PEPROTECH (London, England).  Human 
specific fluorescein isothiocyanate (FITC)-, peridinin chlorophyll (PerCP)- 
and phycoerythrin (PE)-labeled monoclonal antibodies (mAb) were 
purchased from Becton Dickinson (Mountain View, CA, USA). 
Methylcellulose supplemented with a specific mouse cytokine cocktail was 
from Stem Cell Technologies (Vancouver, British Columbia, Canada). 
Interleukin-3 (IL-3), granulocyte colony-stimulating factor (G-CSF), 
granulocyte-macrophage colony-stimulating factor (GM-CSF), stem cell 
factor (SCF) and erythropoietin (EPO) were from Amgen (Thousand Oaks, 
CA, USA).  Recombinant human G-CSF (rhG-CSF, lenograstim) was 
purchased from Italfarmaco (Milan, Italy).  67LR cDNA was cloned into the 
pcDNA3 vector and the resulting plasmid was named 67LR-pcDNA3.  The 
rabbit anti-67LR polyclonal antibody ab711, recognizing both human and 
rodent 67LR was from Abcam (Cambridge, UK); the monoclonal anti-67LR 
antibody MLuC5 were kindly provided by Dr. S. Menard and Dr E. 
Tagliabue (National Cancer Institute, Milan, Italy).  Goat polyclonal anti-a6  
integrin subunit antibody, anti phospo-ERKs and anti-ERK2 polyclonal 
antibodies were from Santa Cruz Biotechnology (Santa Cruz, CA, USA).  
The ELISA kit for quantitative determination of laminin in human sera was 
from TAKARA (Otsu, Shiga, Japan).  
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III.2 Sample collection 
Heparinized blood samples were obtained after informed consent (according 
to the procedures outlined by the ethical committee of our institution) 
before, during and after the mobilizing procedure, from 35 healthy adults (19 
males and 16 females, range 20-55).  The donors received glycosylated rhG-
CSF administered subcutaneously, at 10 µg/kg/day, in two divided doses, for 
5 days, to mobilize and collect CD34+ cells.  Heparinized bone marrow 
specimens were obtained by aspiration from the posterior iliac crest from 
healthy young donors (8 males and 7 females, range 25-45). 
 
III.3 CD34+ hematopoietic stem cell separation 
Peripheral blood (PB) and bone marrow (BM) mononuclear cells (MNC) 
were isolated by Ficoll- Hypaque centrifugation.  CD34+ cells were highly 
purified by MiniMacs high-gradient magnetic separation columns (Miltenyi  
Biotec, Auburn, CA, USA).  CD34+ cells reached 90% purity by 2 sequential 
selections through the magnetic cell separator.  Purity of the positively 
selected CD34+ cells was checked by flow cytometry.  For in vitro cultures 
purified CD34+ cells were resuspended in RPMI medium supplemented with 
5% FCS.  For CD34+/CD38- enrichment, 5x107 PBMNC/mL were incubated 
for 30 minutes in ice with a mixture of antiglycophorin A, -CD3, -CD2, -
________________________________________________________________ 
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CD14, -CD16,-CD19, -CD24, - CD56 and -CD66b tetrameric antibody 
complexes (StemCell Technologies).  After three washings, cells were 
incubated for 30 minutes with 60 ml/mL magnetic colloidal iron/dextran 
particles, and finally processed through the StemSepTM device for depletion 
of targeted cells (StemCell Technologies). At the end of the procedure, the 
amount of CD34+ cell was 60% to 80% and purity in the range 70-95%. 
 
III.4 Flow cytometry analysis 
Enumeration and immunophenotyping of CD34+  cells were performed by 2- 
and 3-color flow cytometry, respectively, in which CD34+ were gated by a 
CD45-gating method.   Briefly, whole blood containing approximately 1x106 
cells was incubated for 20 minutes at 4°C with the following directly 
conjugated monoclonal antibodies: 20µL of both PerCP-labeled anti-CD45 
antibody and PE-conjugated anti-CD34 antibody.  The sample was treated 
with red blood cell lysis buffer (Becton-Dickinson) and the cells were 
washed with PBS containing 1% human serum albumin and 0.1% sodium 
azide.  After treatment with 2% formaldehyde cell fixation buffer (Becton-
Dickinson) for 10 minutes at 37°C, the cells were washed and stained first 
with 1µL of anti-67LR polyclonal antibody ab711 for 30 minutes at 4°C and 
then with a FITC-conjugated anti-rabbit antibody for 30 minutes at 4°C.  
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The cells were analyzed immediately on a FACScan flow cytometer 
(Becton- Dickinson).  At least 5-10x105 total events were acquired in each 
sample using the Cellquest software (Becton-Dickinson).  A mononuclear 
gate was created, based on CD45 expression and side light scatter; the total 
number of CD34+ cells was calculated on the basis of the relative percentage 
of CD34+ cells in the total number of nucleated cells.  The expression of 
67LR on enriched CD34+/CD38- cells was assessed by triple staining using 
an anti-CD34-PerCP, an anti-CD38-PE and the polyclonal anti-67LR 
antibody ab711 detected by a FITC-conjugated anti-rabbit antibody.  
Equivalent gating on isotype-matched negative controls was used for 
background subtraction in all assays. 
 
III.5 Cell cultures 
CD34+ KG1 cell were grown in RPMI supplemented with 5% heat-
inactivated FCS, 300 mg/ml glutamine, 100 U/mL penicillin, and 100 mg/mL 
streptomycin.  5x106 cells were transfected with 10 mg of 67LR-pcDNA3 or 
control vector pcDNA3 and 60 mL of Lipofectamine for 5h at 37°C (5% 
CO2).  Transfected cells were selected by geneticin at 0.4 mg/mL; the 
resulting clones were pooled and cultured in the presence of 0.2 mg/mL 
Geneticin. Clonogenic human progenitors were measured in 
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methylcellulose, as previously described.  Clonogenic mouse progenitors 
were also grown in methylcellulose in the presence of a recombinant mouse 
growth factor cocktail.  The human bone marrow-derived endothelial cell 
line HBMEC was a gift of Dr C. Ellen van der Schoot (Amsterdam, 
Netherlands).  Cells were cultured in FN-coated culture flasks in Medium 
199 supplemented with 10% pooled, heat-inactivated human serum, 10% 
FCS, 1 ng/mL basic fibroblast factor (Boehringer-Mannheim, Mannheim, 
Germany), 5 U/mL heparin, 300 mg/mL glutamine, 100 U/mL penicillin, and 
100 mg/mL streptomycin.  In all experiments, HBMEC monolayers were 
pretreated with IL-1b ?for 4 h (Peprotech, Rocky Hill, NJ, USA). 
 
III.6 Mobilization of mouse CD34+ cells 
Male Balb/c mice with age of 8-9 weeks were purchased from Charles River 
Laboratory (Lecco, Italy).  All the experiments were approved by the animal 
care committee of our institute.  Mice received intraperitoneally a daily dose 
of 300 mg/Kg G-CSF, for 4 days.  Some mice also received intraperitoneal 
injections of the neutralizing anti-67LR antibody MLuC5 (100 mg in 200 mL 
saline) on day 3 and 4, immediately after G-CSF treatment.  Four hours after  
the last injection of G-CSF, mice were sacrified, BM and PB were harvested 
and analyzed by 2-color flow cytometric analysis, using a mouse-specific 
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PE-conjugated anti-CD34 antibody (Becton-Dickinson) and the anti-67LR 
polyclonal antibody ab711, revealed by a FITC-conjugated anti-rabbit 
secondary antibody, as described above. 
 
III.7 Western Blot  
CD34+ KG1 cells, PBMNC, purified PB or BM CD34+ cells were lysed in 
1% Triton X-100/PBS with proteases inhibitors.  100 µg of protein was 
electrophoresed on a 12% SDS-PAGE, under reducing conditions, and 
transferred onto a PVDF membrane.  The membrane was blocked and 
probed with 1 µg/mL of theanti-67LR polyclonal antibody ab711. Finally, 
washed filters were incubated with horseradish peroxidase-conjugated anti-
rabbit antibodies and detected by ECL.  For MAPK activation, KG1 cells, 
highly purified BM CD34+ cells and highly purified G-CSF-mobilized PB 
CD34+ cells were plated in 35 mm wells previously coated overnight at 4°C 
with LM (100 mg/well) or heat-denatured BSA, as a negative control.  Cells 
were allowed to adhere for 16 h at 37°C, lysed and subjected to Western blot 






III.8 Adhesion assay 
96-well microtiter plates were coated overnight at 4°C with LM (5 mg/well) 
or heat-denatured BSA, as a negative control.  Plates were incubated for 16 h 
at 37°C with 1x105 CD34+ KG1 cells, BM CD34+ cells or G-CSF-mobilized 
PB CD34+ cells in 100 µL RPMI medium supplemented with 5% FCS.  
Attached cells were fixed with 3%  paraformaldehyde, permeabilized by 2% 
methanol and stained with 0.5% crystal violet in 20% methanol.  The 
staining was eluted with a solution of 0.1 M sodium citrate, pH 4.2, in 50% 
ethanol, and the absorbance measured at 540 nm.  In some experiments, cells 
were pre-incubated with 1µg of anti-67LR polyclonal antibody ab711 or 
with non-immune rabbit Igs, as a negative control, and then plated on LM.  
All the experiments were performed in triplicate. Results are reported as a 
percentage of control; 100% values represent cell adhesion to heat-
inactivated BSA. 
 
III.9 Cell migration assay 
Cell migration assays were performed in Boyden chambers, using uncoated 
5 µm pore size PVPF polycarbonate filters.  2x105 CD34+ KG1 cells or G-
CSF mobilized PB CD34+ cells were plated in the upper chamber in serum-
________________________________________________________________ 
___________________________________________________________________ 32 
free medium; 25 mg/mL LM or serum-free medium was added in the lower 
chamber.  Cells were allowed to migrate for 90 min at 37°C, 5% CO2.  Cells 
on the lower surface of the filter were then fixed in ethanol, stained with 
hematoxylin and counted at 200x magnification (10 random fields/filter).  In 
some experiments, cells were pre-incubated for 1 h at 37°C with 1 mg/mL 
anti-67LR polyclonal antibody ab711 or with non-immune rabbit Igs and 
then plated.  All the experiments were performed in triplicate. 
 
III.10 Transendothelial migration assay 
Migration assays were performed on FN-coated filters in Transwell plates of 
6.5 mm diameter with 5 mm pore filters.  Endothelial cells were plated at 2-
3x104 cells/Transwell to obtain confluent endothelial monolayers. 
Monolayers of endothelial cells were pre-treated for 4 h with IL-1b? and 
washed with assay medium (DMEM with 0.25% BSA).  1x104 G-CSF-
stimulated BM CD34+ cells were added to the upper compartment in 0.1 mL 
assay medium; 0.6 mL assay medium, with or without SDF-1 (100 ng/mL), 
was added to the lower compartment.  After 4 h incubation at 37°C, 5% 
CO2, cells migrating into the lower compartment as well as non-migrating 
cells into the upper compartment were collected and analyzed for their CFC 
content.  In blocking experiments, G-CSFstimulated BM CD34+ cells were 
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pre-incubated for 30 min at 37°C with with 1 mg/mL anti-67LR polyclonal 
antibody ab711 or with non-immune rabbit Ig.  
 
 
III.11 Statistical analysis 
Results of in vivo and in vitro studies were expressed as a mean ± standard 
error of the mean (SEM) or standard deviation (SD), as required.  
Differences between groups were evaluated using the Student’s t-test. 





§ IV CHAPTER 
 
RESULTS 
IV.1 67LR expression in human G-CSF mobilized CD34+ 
peripheral blood stem cells 
We first analyzed circulating CD34+ cells of normal donors after G-CSF 
treatment to investigate whether there was a modulation of 67LR expression.   
35 healthy donors were treated with G-CSF to induce mobilization and their 
PBMNCs were analyzed at steady-state (day=0) and at various time-points  
(days 3-5).  Phenotypic analysis of 67LR expressing CD34+ cells was 
determined by 3-color flow cytometry on a mononuclear gate of CD45+ 
cells.  G-CSF administration increased 67LR expression in circulating 
CD34+ cells; by contrast, unstimulated BM CD34+ cells showed very low 
levels of 67LR (Fig 1A, B).  The mean percentage ± SEM of 67LR positive 
unstimulated BM CD34+ cells from 15 normal subjects was 5.1±1.1% (range 
1-13%) (Fig.1B).  
Using as cut off a percentage of 67LR positive circulating CD34+ cells 




CSF administration.  The mean percentage ± SEM of 67LR positive 
circulating CD34+ cells was 1.86±0.2% (range 0.5-7%) before G-CSF 
administration and 46.3±4.1% (range 23-86%) on the day of cell harvesting 
(day 4 or 5 of G-CSF administration) (p <0.0001) (Fig. 1C).   67LR 
expression on CD34+ cells was rapidly reduced in all G-CSF-treated donors 
(Fig. 1D) after G-CSF withdrawal.  Noteworthy, 4 of 5 donors not showing 
67LR increase on circulating CD34+ cells after G-CSF treatment can be 
considered poor mobilizers (Fig. 2A and B: donor 5, 11, 19 and 23); indeed, 
they obtained a peak of less than 20 CD34+ cells/mL and did not achieve the 
target CD34+  cell yield =?2x 106 CD34+ cells/kg in one apheresis procedure 
after 5 days of G-CSF administration.  Accordingly, statistic analysis in 
basis of linear regression showed that both numbers and percentages of 
67LR positive circulating CD34+ cells after G-CSF administration directly 
correlated with CD34+ cell peak values on the day of collection (r=0.7, 
p=0.001 and r=0.5, p=0.002, respectively) (Fig. 2C).   
We also investigated 67LR expression by Western blot with an anti-67LR 
polyclonal antibody on highly purified G-CSF-mobilized CD34+ cells and 
on PBMNC from the corresponding donors, collected before and at various 
time points during G-CSF stimulation.  Western blot analysis showed 
increased 67LR expression in PBMNC during G-CSF treatment and 
________________________________________________________________ 
___________________________________________________________________ 36 
confirmed that G-CSF mobilized CD34+ cells expressed high levels of 67LR 
at the time of cell harvesting by apheresis, as compared to unstimulated BM 
HSC (Fig.3A).  
We also investigated 67LR expression in G-CSF-mobilized CD34+/CD38- 
cells, a population enriched in stem cells and characterized by high 
repopulating activity in NOD/SCID mice (60). Phenotypic analysis of 67LR 
expression in enriched CD34+/CD38- cells, as determined by flow cytometry 
on PBMNC from five G-CSF treated donors, showed that the mean ± SEM 
of 67LR expressing CD34+/CD38- cells at day 5 of G-CSF stimulation was 
43±3% (range 36-60%), whereas it was 7.5±2% (range 4-10 %), before G-
CSF administration (Fig.3C).  
  
III.2 G-CSF modulation of CD34+ cell adhesion to laminin 
We also studied 67LR involvement in CD34+ cell adhesion to laminin by in 
vitro cell adhesion assays.  For this purpose we used CD34+ KG1 leukemic 
cells, because of CD34+ antigen, highly purified unstimulated normal BM 
CD34+ cells and highly purified G-CSF mobilized PB CD34+ cells.  All 
these were able to adhere to laminin (Fig.4A).  Different receptors were 
involved in KG1 cell adhesion to laminin; indeed, pre-incubation with anti-
67LR and anti-a6 integrin antibodies caused a 53% and a 56% reduction of 
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cell attachment to laminin, respectively.  Preincubation with anti-67LR 
antibodies did not affect the adhesion to laminin of normal unstimulated  
BM CD34+ cells, expressing low levels of 67LR, whereas anti-a6 integrin 
antibodies caused a 67% reduction of their laminin-dependent cell adhesion.  
Interestingly, G-CSF-mobilized PB CD34+ cells adhered to laminin to the 
same extent as BM CD34+ cells; however, such cell adhesion to laminin was 
almost completely inhibited by anti-67LR antibodies.  Noteworthy, anti-a6 
integrin antibodies did not affect PB CD34+ cell adhesion to laminin, since 
a6 integrin expression was strongly down-regulated during G-CSF-induced 
HSC mobilization.  Indeed, flow cytometry analysis performed on 
BMMNCs obtained from BM of 10 healthy donors and on PBMNCs 
obtained from 10 healthy donors after G-CSF stimulation showed that the 
mean percentage ± SEM of a6 expressing CD34
+ cells was 27.3±3.2%,  
(range 9.6-36.3%) in unstimulated BM CD34+ cells and 4±1.1% (range 0-
10%) in G-CSF mobilized PB CD34+ cells.   
Therefore, 67LR upregulation during G-CSF-induced HSC mobilization 
does not increase CD34+ cell adhesion to laminin.  However, unstimulated 
BM CD34+ cell adhesion to laminin is mostly mediated by a6 integrin 
receptors, whereas G-CSF-mobilized CD34+ cell adhesion to the same 
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substrate is selectively mediated by 67LR, because a6 integrins are down-
regulated during mobilization and replaced by 67LR.   
A laminin promoting effect on KG1 and BM CD34+ cell adhesion and 
migration, largely mediated by a6 integrin receptors, has been already 
reported. Laminin also exerts mitogenic activity on the same cell types . We 
found that 67LR and a6 transduce different signals.  Indeed, we showed 
increased MAPK phosphorylation after KG1 and BM CD34+ cell adhesion 
to laminin (Fig.4B); on the contrary, PB CD34+ cell adhesion to laminin, 
mostly mediated by 67LR engagement, did not increase MAPK activation.  
 
III.3 67LR dependent migration of KG1 and G-CSF mobilized 
CD34+ cells 
We also investigated by in vitro chemotaxis assays whether 67LR up-
regulation could be implicated in increased laminin-dependent CD34+ cell 
migration.  For this purpose, leukemic CD34+ KG1 cells were transfected 
with 67LR cDNA; transfected cells showed a 3.8 fold increase in 67LR 
expression (mean fluorescence index: 170.4 and 634.96 before and after 
transfection, respectively). We showed that 67LR-transfected KG1 cells 
showed increased migration toward laminin, as compared to wild-type cells 
(Fig.4C).  67LR overexpression in transfected KG1 cells did not increase 
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their adhesion to laminin (not shown), demonstrating that 67LR is mainly 
involved in mediating CD34+ cell migration rather than adhesion.  Then, we 
investigated by in vitro chemotaxis assays whether 67LR could mediate G-
CSF-mobilized CD34+ cell migration to laminin; BM CD34+ cells were not 
analyzed being 67LR expression was not significant (Fig.1 and 3A). Highly 
purified PB CD34+ cells from three G-CSF-treated donors migrated toward 
human laminin and cell pre-incubation with anti-67LR antibodies strongly 
reduced the migratory response to laminin (Fig.4D). Therefore, 67LR 
engagement is mainly implicated in laminin dependent CD34+ cell migration 
after G-CSF stimulation.   
 
III.4 Laminin concentrations in human sera during G-CSF-
induced mobilization 
We investigated whether laminin serum concentrations were increased in 
donors after G-CSF administration, thus creating a chemotactic signalling 
toward peripheral blood.  ELISA assays of 15 donor sera obtained before 
(day 0) and after (day 4 or 5) G-CSF-induced CD34+ cell mobilization 
showed that laminin concentration in sera were not modified by the G-CSF 
treatment, being the mean ± SEM of serum laminin concentration 256±78 
ng/mL and 268.2±66 ng/mL, before and after G-CSF administration, 
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respectively.  Thus, it seems that increased 67LR expression in circulating 
CD34+ cells during G-CSF-induced HSC mobilization participates in their 
migration toward laminin, even though a laminin gradient between BM and 
peripheral blood is not created. 
 
III.5 67LR expression in BM CD34+ cells after in vitro G-CSF 
treatment and its involvement in trans-endothelial migration 
We investigated by in vitro experiments whether G-CSF was able to directly 
increase 67LR expression in normal BM CD34+ cells. Three-color flow 
cytometric analysis of BM CD34+ cells from three normal donors, cultured 
for 24 and 48 h in medium with or without 200 ng/mL G-CSF, showed 
increased 67LR expression after in vitro G-CSF treatment (mean 
percentages ± SEM of 67LR expressing CD34+ cells: 8±4% vs 25±3% and 
33±4% without and with G-CSF at 24 and 48h, respectively; both p: 
<0.0001) (Fig.5A). By contrast, a6 integrin expression decreased after in 
vitro G-CSF treatment (mean percentages ± SEM of a6 integrin expressing 
CD34+ cells: 33.3±3.1% vs 14.7± 4% and 7.1± 2% without and with G-CSF 
at 24h and 48 h, respectively; both p: <0.0001) (Fig.5B).  Interestingly, in 
vitro G-CSF-treated BM CD34+ cells, expressing high levels of 67LR, 
showed a further increase of this receptor after contact with BM derived 
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endothelial cell layers (mean percentages ± SD of 67LR expressing G-CSF-
treated CD34+ cells: 25±4% and 45±5% before and after co-culture with 
endothelial cells, respectively; p: <0.0001) (Fig.5B), suggesting that marrow 
CD34+ cells 67LR up-regulation in response to G-CSF can be further 
increased by adhesion to endothelium. Thus, G-CSF-induced 67LR 
expression in BM CD34+ cells could participate in their egress from BM by 
mediating adhesion and trans-migration through laminin, as formerly 
documented for T lymphocytes and cancer cells.  Therefore, we investigated 
whether 67LR could promote trans-endothelial migration of in vitro G-CSF-
stimulated BM CD34+  cells, expressing high levels of 67LR  (Fig.5A).  
SDF-1-dependent trans-endothelial migration of G-CSF-stimulated BM 
CD34+ cells was strongly affected by pre-incubation with polyclonal anti-
67LR antibodies (Fig.5C), thus suggesting that G-CSF-mediated 67LR up-
regulation contributes to CD34+ cell migration across the BM endothelium, 
an important step in CD34+ cell trafficking from and to BM. 
 
III.6 67LR expression in mouse BM CD34+ cells after G-CSF-
induced HSC mobilization 
We investigated whether 67LR up-regulation in response to G-CSF could 
occur in BM CD34+ cells also in vivo, thus possibly playing a role in their 
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egress from BM.  Male Balb/c mice were treated daily for 4 days with intra-
peritoneal injections of 300 mg/Kg G-CSF or saline, as a control; four hours 
after the last injection, PB and BM were analyzed by flow cytometry. 
Murine mobilization experiments were performed four times, each group 
being composed of 4 mice.  As already observed in human CD34+ cell 
mobilization (Fig.1), G-CSF treatment induced 67LR up-regulation in 
mouse PB CD34+ cells (mean percentage ± SEM of 67LR positive PB 
CD34+ cells before and  after G-CSF treatment: 11.5±2% vs 47.3±8.2%, 
respectively; p: <0.0001).  Interestingly, G-CSF increased 67LR expression 
also in mouse BM CD34+ cells (mean percentage ± SEM of 67LR positive 
BM CD34+ cells before and after G-CSF treatment: 12.5±0.3% vs 62±4.1%, 
respectively; p <0.0001) (Fig.6A).  These findings demonstrate that G-CSF 
administration increases 67LR expression in BM CD34+ cells, confirming 
what observed by in vitro stimulation experiments.  
 
III.7 Effects of 67LR inhibition on G-CSF-induced HSC 
mobilization 
We then investigated whether the increased 67LR expression in BM CD34+ 
cells could be involved in their egress from BM, during G-CSF-induced 
mobilization.  To interfere with 67LR function, we injected a neutralizing 
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anti-67LR antibody into Balb/c mice on days 3 and 4 of mobilization, 
immediately after each G-CSF stimulation, and examined its effect on 
mobilization.  We observed a significantly reduced number of mobilized 
CD34+ cells (Fig.7B) and of circulating progenitor cells, evaluated as colony 
forming cells (CFC) (Fig.7C).  In a control group of G-CSF-treated mice, 
nonimmune antibodies did not significantly affect the number of circulating 
CD34+ cell and progenitor cells (Fig.7A and B).  Total BM cellularity did 
not change in MLuC5-treated mice, as compared to controls.  In addition, 
percentages of 67LR positive CD34+ cells in the BM of MLuC5- and non 
immune Ab-treated mice were similar, demonstrating that the inhibition of 
CD34+ cell mobilization occurred without affecting BM-resident CD34+ 
cells (Fig.7C).  The attenuation of HSC mobilization in mice was obtained 
by using the neutralizing anti-67LR antibody MLuC5, which is an IgM; 
therefore, we had to exclude that circulating 67LR positive CD34+ cells 
could have been removed by complement-mediated lysis.  Our results were 
confirmed in the C5 deficient Mba/2Jstrain, in which we also observed a 
significant reduction of CD34+ cell mobilization after 67LR inhibition. The 
efficiency of mobilization in this strain was evaluated by comparing the 
mean ± SEM of PB CD34+ cells in saline-treated mice (20.7/mL±3.3%) to 
that of G-CSF-treated mice (99.8/mL±24.2%): p‹ 0.05.  MluC5 treatment 
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strongly decreased mobilization; indeed, the mean ± SEM of PB CD34+ cells 
in mice treated with G-CSF plus control antibody was 67.1/mL±11.2% 
whereas it was 39.2/mL±7.6% in mice treated with G-CSF plus MLuC5: p‹ 
0.05.  Non-immune antibody did not affect the efficiency of G-CSF induced 
mobilization, since the slight decrease in mobilized CD34+ cells, as 
compared to G-CSF alone (67.1/mL vs 99.8/mL), was not statistically 
significant (p=0.134).  In C5 deficient mice, C3-mediated clearance of 67LR 
positive CD34+ cells might still occur.  However, WBC counts in PB were 
not significantly modified by MLuC5 antibody treatment, as compared to 
controls (not shown).  Since many types of circulating WBC, such as 
monocytes, T lymphocytes and neutrophils, are 67LR positive, a non-




























In vivo G-CSF administration increases 67LR expression in circulating CD34+ cells as compared to normal 
unstimulated marrow CD34+ cells.  
Panel A: 67LR expression in circulating CD34+ cells during G-CSF-induced stem cell mobilization in 2 
representative donors (n. 1 and 20 in figure 2A and 2B). Immunophenotyping of 67LR expressing CD34+ cells 
was performed by 3-color flow cytometry on mononuclear cells gated for side light scatter (SSC-H) and CD45+, 
with an anti-67LR polyclonal antibody (Ab) detected by a FITC-conjugated anti-rabbit Ab. Peripheral blood 
mononuclear cells (PBMNC) were collected before (day 0) or at various time -points (day 3 and 5) during G-CSF 
administration.  
Panel B: Immunophenotyping of 67LR expressing CD34+ cells on BMMNC from 3 representative normal 
subjects.  
Panel C: Percentage (%) of 67LR expressing CD34+ cells in bone marrow mononuclear cells (BMMNC) from 15 
normal subjects and in PBMNC collected from 35 healthy donors before G-CSF administration (day 0,n) or at 
the time of cell harvesting (day 5,    ).  
Panel D: Immunophenotyping of 67LR expressing CD34+ cells performed by 3-color flow cytometry on 
mononuclear cells gated for side light scatter (SSC-H) and CD45+, with an anti-67LR polyclonal Ab on PBMNC 
collected before (day 0), during (day 3 and 5) G-CSF administration and at G-CSF withdrawal (day 6 and 9). 





Increased 67LR expression in circulating  CD34+  cells  after  G-CSF  administration  is significantly 
correlated with mobilization efficiency.  
Panel A: Percentage (%) of 67LR expressing CD34+ cells in PBMNC collected from 35 healthy donors before G-
CSF administration (day 0,n) or at the time of cell harvesting (day 5,  ). Mean percentages ± SEM of 67LR 
positive circulating CD34+ cells were 2.36±0.4% before G-CSF administration and 42.4±4.1% on the day of cell 
harvesting (p <0.00001). 
Panel B: 67LR expressing CD34+ cells/? L in PBMNC collected from 35 healthy donors  at  the  time  of  cell  
harvesting  (day  5  of  G-CSF administration,    )  and the corresponding peak value of CD34+ cells /? l (   ). Mean 
± SEM of 67LR positive circulating CD34+ cells was 0.11±0.02/? L befo re G-CSF administration and 
29.6±4.2/? L on the day of cell harvesting (p<0.00001). 4/5 poor mobilizing donors (*) did not show 67LR 
increase in circulating CD34+ cells.  
Panel C: Pearson’s linear regression analysis between percentages of 67LR expressing PB CD34+  cells/? L after 
G-CSF administration and PB CD34+ cell peak values on the day of collection (r=0.5, p=0.002). Percentages of 









67LR expression increases in circulating CD34+ and CD34+/CD38- cells during G-CSF administration.  
Panel A: Western blot analysis with an anti-67LR polyclonal Ab of PBMNC collected from 2 representative 
donors before (day 0) or at different time-points (day 3 and 5) of G-CSF administration, of highly purified 
circulating CD34+ cells collected from the same donors at day 5 of G-CSF administration and of highly 
purified BM CD34+ cells collected two different donors. Treatment by G-CSF increases 67LR production, 
especially in CD34+ cells. 
Panel B:  67LR expression in CD34+/CD38- progenitor cells during G-CSF-induced stem cell mobilization 
from a representative case. Immunophenotyping of 67LR expressing cells was performed on enriched 
CD34+/CD38- cells (see material and methods) collected at day 0 (upper panel)  and 5 (lower panel) of G-
CSF administration on a mononuclear gate by triple staining with a PeRCP-conjugated anti-CD34, a PE-
conjugated anti-CD38 and an anti-67LR polyclonal Ab detected by a FITC-conjugated anti-rabbit Ab. 
CD34+/CD38- cells expressing 67LR were evaluated within the gate of CD34+CD38- cells (circled). 





67LR mediates in vitro  cell adhesion and migration to laminin of G-CSF mobilized CD34+ cells and affects MAPK 
phosphorylation in these cells.  
Panel A: In vitro  cell adhesion to laminin of KG1, unstimulated BM and G-CSF-mobilized PB CD34+ cells. KG1 cells, 
highly purified BM CD34+ cells from three donors and highly purified G-CSF-mobilized PB CD34+ cells from three 
donors were plated in wells coated with human placental laminin (5 ?g/well), after pre -incubation with non immune 
rabbit antibodies (n), an anti 67LR polyclonal Ab (   ), an anti ? 6 Ab (   ), and allowed to adhere for 16 h at 37°C. As 
negative controls, heat-denatured BSA was used for coating. Attached cells were fixed and stained with crystal violet; 
the absorbance (OD) of the eluted stain was measured by a spectrophotometer at 540 nm. All experiments were 
performed in triplicate and reported as a percentage of total cell input. Results are presented as mean ± SD. 67LR 
supports cell adhesion to laminin of KG1 and G-CSF mobilized CD34+ cells, while adhesion to laminin of unstimulated 
marrow CD34+ cells is 67LR-independent and mostly mediated by ? 6 integrins. 
Panel B : MAPK activation in CD34+ cell adhered to laminin. KG1 cells, highly purified unstimulated BM CD34+ cells 
and highly purified G-CSF-mobilized PB CD34+ cells were plated in 35 mm wells coated with human placental laminin 
and allowed to adhere for 16 h at 37°C. As negative controls, heat-denatured BSA was used for coating. Cells were then 
lysed and subjected to Western blot with anti-phospho -ERKs and anti-ERK 2 (as a loading control) polyclonal 
antibodies. Adhesion to laminin increased MAPK phosphorylation in both KG1 and BM CD34+ cells whereas PB CD34+  
cell adhesion to laminin, mostly mediated by 67LR engagement, did not increase MAPK activation. 
Panel C: In vitro  cell migration to laminin of wild type (  ) and 67LR-transfected (  ) KG1cells. After incubation with 
non immune Ab (-) and a polyclonal anti-67LR Ab (pAb anti-67LR), KG1 cells were plated in Boyden chambers and 
allowed to migrate toward human placental laminin (25 ? g/mL). 100% values represent cell migration in the absence of 
chemoattractant. Values are the mean ± SD of three experiments performed in triplicate. Laminin-induced migration is 
increased in 67LR-transfected KG1 cell and is strongly reduced by blocking 67LR.  
Panel D: In vitro  cell migration to laminin of G-CSF-mobilized PB CD34+ cells (  ). After incubation with non immune 
Ab (-) and a polyclonal anti 67LR Ab (pAb anti-67LR), highly purified G-CSF mobilized CD34+ cells were plated in 
Boyden chambers and allowed to migrate toward human placental laminin. 100% values represent cell migration in the 
absence of chemoattractant. Values are the mean ± SD of three experiments performed in triplicate. Laminin -induced 




67LR is up-regulated by G-CSF and by exposure to BM-derived endothelial cells in human BM CD34+ cells and 
is involved in their trans-endothelial migration.  
Panel A: 67LR and a6 integrin expression on BM CD34+ cells  after in vitro  G-CSF treatment, in one representative 
experiment. BMMNCs from normal donors were cultured for 24 and 48 h with medium alone or in presence of 200 
ng/mL G-CSF and analyzed by 3-color flow cytometry on mononuclear cells gated for side light scatter (SSC-H) and 
CD45+, with anti-67LR and anti-? 6 polyclonal Abs or non-immune polyclonal Abs, as a negative control, and detected 
by a FITC-conjugated anti-rabbit Ab. 67LR expression on human BM CD34+ cells is increased by in vitro G-CSF 
treatment, whereas ? 6 integrin expression decreases.  
Panel B: 67LR expression on BM CD34+ cells  after in vitro  G-CSF treatment and exposure to BM-derived endothelial 
cells, in one representative experiment. BMMNC from normal donors were cultured for 24h with medium alone, in the 
presence of 200 ng/mL G-CSF, or on confluent endothelial cell layers in the presence of 200 ng/mL G-CSF, and 
analyzed by 3-color flow cytometry, as above described. 67LR expression of human G-CSF-stimulated BM CD34+ 
cells is further increased by exposure to BM-derived endothelial cells. 
Panel C: Transendothelial migration of G-CSF-stimulated BM CD34+ cells. After incubation with a polyclonal anti 
67LR Ab or a non immune Ab, CD34+ cells, stimulated for 72 h with 200 ng/mL G-CSF, were plated in Transwell 
plates coated with confluent endothelial monolayers and allowed to migrate toward 200 ng/mL SDF1 (  ) or medium 
alone for 4 h (  ). Cells migrating into the lower compartment were collected and analyzed for their colony-forming 
cells (CFC) content by methyl-cellulose colony assay. Data are the mean ± SEM of three separate experiments, *** = 






















G-CSF increases 67LR expression in mouse BM and PB CD34+ cells.  
67LR expression on PB CD34+ cells and on BM CD34+ cells before (central panels) and after G-CSF 
administration (right panels) from one representative mouse. BALB/c mice were treated daily for five days 
with 300 ?g/Kg G-CSF or with saline, as a control. Four hours after the last injection, PB and BM CD34+  
cells were analyzed by flow cytometry, with a mouse-specific anti-CD34-PE Ab and with an anti-67LR 




Increased 67LR expression in BM CD34+ cells is involved in G-CSF-induced mobilization of murine HSCs.  
Panel A: G-CSF-mobilized CD34+ cells after treatment with anti-67LR antibodies. Balb/c mice were treated daily 
for four days with 300 ?g/Kg G-CSF (n ) or saline  (  ), as a control. Non-immune (  ) or the MLuC5 neutralizing 
anti-67LR monoclonal Abs (  ) were injected into G-CSF-treated mice on days 3 and 4 of mobilization, 
immediately after each G-CSF stimulation. Four hours after the last injection, PB CD34+ cells were evaluated by 
flow cytometry, with a mouse-specific anti-CD34-PE antibody. Data are mean ± SEM of three separate 
experiments, each group being composed of 4 mice; **= p < 0.001 
Panel B: G-CSF-mobilized progenitors after treatment with anti-67LR antibodies. Balb/c mice were treated daily 
for four days with 300 ?g/Kg G-CSF (n ) or saline  (   ), as a control. G-CSF-treated mice were injected with non-
immune (   ) or MLuC5 neutralizing anti-67LR Abs (  ) on days 3 and 4 of mobilization, immediately after each G-
CSF stimulation. Four hours after the last injection, the number of progenitors mobilized into the circulation was 
evaluated by colony assays and reported as the number of CFC x 103/mL. Data are mean ± SEM of three separate 
experiments, each group being composed of 4 mice; *** = p < 0.0001. Mobilization of murine progenitor cells, 
evaluated both as circulating CD34+ cells and as CFC, is significantly inhibited by anti-67LR antibodies. 
Panel C: 67LR expression BM CD34+ cells in a representative mouse treated with non immune (left panels) and 
MLuC5 (right panels) Abs. Total BM cellularity (upper panels) as well as the percentage of 67LR positive BM 
CD34+ cells (lower panels) in non immune Ab and MLuC5-treated mice were similar, thus excluding both a 
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DISCUSSION 
Mobilized hematopoietic stem cells (HSCs) obtained after cytokines 
treatment are rapidly replacing traditional bone marrow harvest as a source 
of stem cells for transplantation purposes (89).  Several observations suggest 
that the HSCs mobilization is a mechanism similar to the enhancement of 
the physiological stem cell release after stress signal (60).  
During stem cell mobilization, the adhesion profile of HSCs changes 
facilitating their egress from bone marrow (65, 90). Adhesion molecules 
exstablish interactions between HSCs and cellular and matrix components in 
the BM environment.   These adhesive interactions play an important role in 
the retention of HSCs within the BM microenvironment (91).  Direct in vivo 
studies showed that HSC release from bone marrow also bears to activation 
of a protease’s coalition.  (92, 65). Therefore, HSC mobilization resembles 
leukocyte recruitment to inflammatory sites and cancer-cell migration; all 
these phenomena likely share common biochemical mechanisms. 
Inflammatory cells, metastasizing cells, and mobilized HSCs have to migrate 
through the blood-vessel wall; subendothelial basement membrane proteins, 
such as laminin, fibronectin, and collagen, regulate cell migration and 
________________________________________________________________ 
___________________________________________________________________ 53 
responsiveness to cytokines by interacting with cell-surface adhesion 
receptors. We investigated a possible role of 67LR, a non-integrin cell-
surface receptor for laminin that plays a key role in tumor invasion and 
metastasis (8), during G-CSF-induced CD34+ HSC mobilization.  We 
showed that after G-CSF stimulation 67LR expression increases in 
circulating CD34+ cells, as compared with unstimulated BM CD34+ cells. 
Numbers and percentages of 67LR positive circulating CD34+ cells after G-
CSF administration significantly correlated with the efficiency of CD34+ cell 
mobilization; indeed, poor mobilizing donors did not show 67LR increase in 
circulating CD34+ cells. We investigated whether during G-CSF 
administration 67LR could be involved in CD34+ cell adhesion to laminin, 
as reported for lymphocytes, leukemic cells, cancer cells and endothelial 
cells.  Unexpectedly, unstimulated BM adhered to laminin to the same extent 
as G-CSF mobilized CD34+ cells; even though the latter expressed a higher 
level of 67LR.  However, different receptors were involved in transducing 
laminin effects.  Adhesion to laminin of unstimulated BM CD34+ cells was 
regulated via a6 integrins, whereas G-CSF-mobilized CD34+ cells adhered 
to laminin exclusively through 67LR.  It seems that BM is the first 
anchoring site for unstimulated CD34+ cells, where anchor to laminin  and 
move to migration and proliferation during steady-state conditions are 
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mediated by integrin receptors. After G-CSF stimulation, CD34+ cell release 
from BM into the circulation requires the expression of 67LR, which 
replaces downregulated a6 integrins in mediating CD34+ cell attachment to 
laminin.  In fact, we demonstrated that 67LR upregulation in transfected 
KG1 cells did not modify cell adhesion to laminin but increased their 
migration toward the same substrate. We also found a6 integrin down-
regulation in circulating CD34+ cells, as compared to steady-state BM. Our 
observations are in agreement with other reports that showed decreased 
expression and activity of other integrins, such as a4 and a5, during HSC 
mobilization.  In addition, a6 integrins are not involved in HSC mobilization 
whereas they promotes progenitor cell homing and engraftment to BM of 
lethally irradiated mice (93).   
In our hypothesis 67LR could be involved in HSC mobilization through a 
mechanism recently proposed for tumor cells. After binding to laminin, 
67LR induce a conformational modification of laminin which increases its 
degradation rate and the release of chemotactic fragments.  It seems that, 
67LR overexpression in cancer cells increases their invasiveness by up-
regulating the expression and the activity of proteolytic enzymes able to 
degrade the extracellular matrix, such as membrane type 1 matrix 
metalloproteinase (MT1-MMP), stromelysin 3, cathepsin L and the matrix 
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metalloproteinase MMP-2. Proteolytic degradation of matrix became a key 
step to facilitate cancer cell migration and HSC mobilization.  G-CSF 
induced 67LR up-regulation could generate changes in BM CD34+ cells 
similar to those acquired by tumor cells; indeed, matrix metallo-proteases, 
such as MT1-MMP and MMP-2, are expressed by human CD34+ 
progenitors and are needed for in vivo mobilization (94, 95); they also could 
be secreted by circulating but not BM CD34+ cells (96).  Interestingly, 
circulating CD34+ cells are mostly quiescent and in the G0/G1phase of the 
cell cycle, even during G-CSF administration (97).  G-CSF-induced 67LR 
upregulation in BM CD34+ cells could be involved in transducing migratory 
signals upon binding to laminin, without inducing cell proliferation, unlike 
integrins.  Indeed, we found that adhesion to laminin determined a reduced 
activation of MAPK in PB CD34+ cells, as compared to KG1 and BM 
CD34+ cells; a phenomenon that could be related to 67LR-mediated 
activation of dual specific phosphatases, as already reported in tumor cells 
(40) and by 67LR in vitro interaction with protein phosphatase-1 (98).  
We also provide evidence that G-CSF-induced 67LR up-regulation on 
CD34+ cell mediates their migration toward laminin.  Although we could not 
document the creation of a laminin gradient from BM to blood during 
mobilization, we cannot exclude the possibility that it may be generated 
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locally and/or transiently by laminin degradation, due to the increased 
proteolytic enzyme production in the BM, after G-CSF administration.  In 
vitro exposure to G-CSF increased 67LR expression in normal human BM 
CD34+ cells, confirming G-CSF direct involvement in the modulation of 
67LR expression during in vivo administration.  We also found that G-CSF-
treated human BM CD34+ cells, expressing high levels of 67LR, showed a 
further increase of such a receptor after adhesion to BM-derived endothelial 
cell layers, thus suggesting a possible role of 67LR in BM CD34+ cell intra- 
vasation, in response to G-CSF.  Indeed, 67LR regulated G-CSF-stimulated 
human BM CD34+ cell transendothelial migration toward SDF-1, a key 
chemokine in HSC trafficking from and to BM.   
These observations led us to investigate the involvement of 67LR in the 
mobilization process by injection of G-CSF and anti-67LR antibodies into 
BALB/c mice.  After G-CSF administration, 67LR expression was increased 
in circulating CD34+ cells, as observed in humans.  In addition, 67LR was 
also up-regulated in BM CD34+ cells and strongly contributed to their 
migration into the circulation; indeed, anti-67LR antibodies significantly 
reduced G-CSF-induced CD34+ and progenitor cell mobilization.  These data 
provide the first in vivo evidence that 67LR plays an important role in stem 
cell egress from BM in response to G-CSF.   
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All together, our data document that 67LR expression is increased in G-CSF 
mobilized CD34+ cells as compared with unstimulated BM CD34+ cells. 
Noteworthy, the level of 67LR expression in circulating CD34+ cells 
significantly correlates with the mobilization efficiency.  Up-regulated 
67LR, which replaces a6 integrin receptors after G-CSF stimulation, is 
required for an efficient HSC mobilization.  Indeed, G-CSF administration 
increases 67LR expression in BM HSCs and contributes to their migration 
into the circulation most probably by mediating their trans-endothelial 
migration. Interestingly, 67LR overexpression, which is peculiar of 
metastatic cancer cells, occurs also in BM and circulating CD34+ stem cells 
after G-CSF stimulation, as well as in BM and circulating CD34+ leukemic 
cells (unpublished observation).  Thus, an intriguing parallel can be drawn 
between cytokine-stimulated hematopoietic stem cells, leukemic cells and 
metastatic cells from solid tumors (99); indeed, a similar signalling pathway, 
led by 67LR activation, is involved in cell adhesion, motility and 
dissemination in all these different cell types.  These findings further support 
a model where HSC mobilization could represent a physiologic counterpart 
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